Gemcitabine-Loaded Microbeads for Transarterial Chemoembolization of Rabbit Renal Tumor Monitored by F-FDG Positron Emission Tomography/X-Ray Computed Tomography Imaging

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Jan 8

PMID 39771587

Authors

Xiaoli Zhang

Tingting Li

Jindong Tong

Meihong Zhou

Zi Wang

Xingdang Liu

Wei Lu

Jingjing Lou

Qingtong Yi

Affiliations

Soon will be listed here.

Abstract

Background/objectives: The purpose of this study was to develop the gemcitabine-loaded drug-eluting beads (G-DEBs) for transarterial chemoembolization (TACE) in rabbit renal tumors and to evaluate their antitumor effect using 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/X-ray computed tomography (F-FDG PET/CT).

Methods: DEBs were prepared by polyvinyl alcohol-based macromer crosslinked with -acryl tyrosine and ,'-methylenebis(acrylamide). Gemcitabine was loaded through ion change to obtain G-DEBs. Their particle size and drug release profile were characterized. VX2 tumors were implanted in the right kidney of rabbits to establish the renal tumor model. The tumor-bearing rabbits received pre-scan by F-FDG PET/CT, followed by targeted transarterial injection of G-DEBs under digital subtraction angiography (DSA) guidance. The rabbits received another F-FDG PET/CT scan 10 or 14 days after the treatment. The therapeutic effect was further validated by histopathological analysis of the dissected tumors.

Results: The average particle size of the microspheres was 58.06 ± 0.50 µm, and the polydisperse index was 0.26 ± 0.002. The maximum loading rate of G-DEBs was 18.09 ± 0.35%, with almost 100% encapsulation efficiency. Within 24 h, GEM was eluted from G-DEBs rapidly and completely, and more than 20% was released in different media. DSA illustrated that G-DEBs were delivered to rabbit renal tumors. Compared with the untreated control group with increased tumor volume and intense F -FDG uptake, the G-DEBs group showed significant reductions in tumor volume and maximum standard uptake value (SUV) 10 or 14 days after the treatment. Histopathological analysis confirmed that the proliferating area of tumor cells was significantly reduced in the G-DEBs group.

Conclusions: Our results demonstrated that G-DEBs are effective in TACE treatment of rabbit VX2 renal tumors, and F-FDG PET/CT provides a non-invasive imaging modality to monitor the antitumor effects of TACE in renal tumors.

References

Iqbal R, Yaqub M, Bektas H, Oprea-Lager D, de Vries E, Glaudemans A . [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant. Clin Cancer Res. 2023; 29(11):2075-2084. DOI: 10.1158/1078-0432.CCR-22-2720. View

Yeh C, Chen S, Chen Y . Delayed diuretic FDG PET/CT scan facilitates detection of renal urothelial cell carcinoma. Clin Nucl Med. 2009; 34(11):829-30. DOI: 10.1097/RLU.0b013e3181b81df4. View

Bi Y, Shi X, Ren J, Yi M, Han X . Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads. Sci Rep. 2022; 12(1):8136. PMC: 9113996. DOI: 10.1038/s41598-022-12334-x. View

Rose T, Kim W . Renal Cell Carcinoma: A Review. JAMA. 2024; 332(12):1001-1010. PMC: 11790279. DOI: 10.1001/jama.2024.12848. View

Miao Y, Ni Y, Bosmans H, Yu J, Vaninbroukx J, Dymarkowski S . Radiofrequency ablation for eradication of renal tumor in a rabbit model by using a cooled-tip electrode technique. Ann Surg Oncol. 2001; 8(8):651-7. DOI: 10.1007/s10434-001-0651-y. View

Capitanio U, Bensalah K, Bex A, Boorjian S, Bray F, Coleman J . Epidemiology of Renal Cell Carcinoma. Eur Urol. 2018; 75(1):74-84. PMC: 8397918. DOI: 10.1016/j.eururo.2018.08.036. View

Han H, Li S, Zhong Y, Huang Y, Wang K, Jin Q . Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy. Asian J Pharm Sci. 2022; 17(1):35-52. PMC: 8888143. DOI: 10.1016/j.ajps.2021.06.001. View

Song S, Deng C, Wen L, Liu J, Wang H, Feng D . 18F-FDG PET/CT-related metabolic parameters and their value in early prediction of chemotherapy response in a VX2 tumor model. Nucl Med Biol. 2010; 37(3):327-33. DOI: 10.1016/j.nucmedbio.2009.12.002. View

He Y, Yuan T, Wang X, Shen M, Ding L, Huang L . Temperature sensitive hydrogel for preoperative treatment of renal carcinoma. Mater Sci Eng C Mater Biol Appl. 2020; 111:110798. DOI: 10.1016/j.msec.2020.110798. View

10.

Qian Y, Liu Q, Li P, Han Y, Zhang J, Xu J . Highly Tumor-Specific and Long-Acting Iodine-131 Microbeads for Enhanced Treatment of Hepatocellular Carcinoma with Low-Dose Radio-Chemoembolization. ACS Nano. 2021; 15(2):2933-2946. DOI: 10.1021/acsnano.0c09122. View

11.

Liapi E, Geschwind J, Vali M, Khwaja A, Prieto-Ventura V, Buijs M . Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor. J Nucl Med. 2011; 52(2):225-30. PMC: 4337871. DOI: 10.2967/jnumed.110.083162. View

12.

Grinberg O, Gedanken A, Ranjan Patra C, Patra S, Mukherjee P, Mukhopadhyay D . Sonochemically prepared BSA microspheres containing Gemcitabine, and their potential application in renal cancer therapeutics. Acta Biomater. 2009; 5(8):3031-7. DOI: 10.1016/j.actbio.2009.05.003. View

13.

Gao F, Rafiq M, Cong H, Yu B, Shen Y . Current research status and development prospects of embolic microspheres containing biological macromolecules and others. Int J Biol Macromol. 2024; 267(Pt 2):131494. DOI: 10.1016/j.ijbiomac.2024.131494. View

14.

Hou G, Zhao D, Jiang Y, Zhu Z, Huo L, Li F . Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma. Cancer Imaging. 2021; 21(1):25. PMC: 7908760. DOI: 10.1186/s40644-021-00393-8. View

15.

Wright B, Johnson B, Vassar M, Saidian A, Rais-Bahrami S, Gunn A . Trans-arterial embolization of renal cell carcinoma: a systematic review and meta-analysis. Abdom Radiol (NY). 2022; 47(6):2238-2243. DOI: 10.1007/s00261-022-03502-8. View

16.

Dubey R, Saneja A, Gupta P, Gupta P . Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine. Eur J Pharm Sci. 2016; 93:147-62. DOI: 10.1016/j.ejps.2016.08.021. View

17.

Singhal S, Singhal J, Figarola J, Riggs A, Horne D, Awasthi S . 2'-Hydroxyflavanone: A promising molecule for kidney cancer prevention. Biochem Pharmacol. 2015; 96(3):151-8. DOI: 10.1016/j.bcp.2015.04.022. View

18.

Natu J, Nagaraju G . Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies. Cancer Lett. 2023; 573:216382. DOI: 10.1016/j.canlet.2023.216382. View

19.

Lewis A, Dreher M . Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. J Control Release. 2012; 161(2):338-50. PMC: 3351580. DOI: 10.1016/j.jconrel.2012.01.018. View

20.

Bi Y, Zhang B, Ren J, Han X, Wu W . Clinical outcomes of gemcitabine-loaded callispheres drug-eluting beads for patients with advanced and inoperable lung cancer: A case series study. Front Pharmacol. 2022; 13:992526. PMC: 9556694. DOI: 10.3389/fphar.2022.992526. View